Ludatscher J I
Netanya Psychiatric Hospital, Israel.
J Clin Psychopharmacol. 1989 Feb;9(1):39-41.
Thirty-five adult chronic schizophrenic patients who had had severe persistent tardive dyskinesia for many years and who had received long-term neuroleptic therapy were treated with small repeated doses of L-dopa. After 4 weeks of treatment the intensity and frequency of involuntary movements decreased, and after 3 months orofacial and choreoathetotic dyskinetic movements diminished very much in all patients. Discontinuation of L-dopa therapy in 10 patients resulted in the return of involuntary movements after 6 weeks. Readministration of the same dose of L-dopa produced the previous therapeutic effects in all patients. Using the NIMH Abnormal Involuntary Movement Scale, the patients were rated severe (4) before treatment and mild (2) after treatment. Maintenance of all 35 patients on daily haloperidol 15 mg, or its neuroleptic equivalent, and small repeated doses of L-dopa induced a stable remission of all involuntary dyskinetic movements for the study year. The placebo control group remained unchanged with the same severe persistent dyskinetic manifestations.
35名成年慢性精神分裂症患者多年来患有严重持续性迟发性运动障碍,且接受了长期抗精神病药物治疗,他们接受了小剂量重复给予左旋多巴的治疗。治疗4周后,不自主运动的强度和频率降低,3个月后,所有患者的口面部和舞蹈手足徐动样运动障碍明显减轻。10名患者停用左旋多巴治疗6周后,不自主运动复发。再次给予相同剂量的左旋多巴后,所有患者均产生了先前的治疗效果。使用美国国立精神卫生研究所异常不自主运动量表,患者治疗前评分为重度(4分),治疗后为轻度(2分)。35名患者每日服用15mg氟哌啶醇或其等效抗精神病药物,并小剂量重复给予左旋多巴,在研究年度内所有不自主运动障碍均得到稳定缓解。安慰剂对照组的严重持续性运动障碍表现无变化。